Buy & Sell Gilead Sciences, Inc. (GILD) – Gilead Sciences, Inc. Price Today
Aura AI Summary
Key Stats
- $160.88BMarket Cap
- HealthSector
- -17.72%3M Drawdown
- $175.41BEnterprise Value
- 2.53%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 92 daysTypical Hold Time
Gilead Sciences, Inc. (GILD) is currently valued at a market capitalization of $160.88B, with an enterprise value of $175.41B. Over the past 52 weeks, Gilead Sciences, Inc. has traded between a low of $102.5 and a high of $155.8, highlighting its annual price range. Over the past three months, Gilead Sciences, Inc. has recorded a drawdown of -17.72%, reflecting recent price volatility. Gilead Sciences, Inc. offers a dividend yield of 2.53%, with the most recent dividend of $0.82 paid on 13 Mar 26. On average, investors hold Gilead Sciences, Inc. for approximately 92 days, indicating typical investor behavior on the platform.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Most Recent News
Inflation rise and US-China trade talks spark volatility in Treasury yields, gold, silver, and stocks.
Recent inflation data shows accelerating price pressures, especially from energy costs, keeping the Federal Reserve cautious and supporting higher Treasury yields and a strong US dollar. The Trump-Xi meeting improved market sentiment but lacked confi...
Bill C-22 sparks global tech backlash over risks to Canada's digital economy and privacy.
Canada's proposed Bill C-22 faces strong opposition from major tech firms like Meta, Apple, and Signal, as well as VPN providers, due to concerns it could force companies to weaken encryption and compromise digital privacy. Industry leaders warn this...
Bill C-22 risks harming Quebec's tech economy by driving away investments and data centers.
Bill C-22 in Canada faces strong opposition from tech leaders and experts who warn it threatens the digital economy by undermining data privacy and encryption. Quebec's tech sector, especially in AI and cloud infrastructure, could lose investments, t...